The UK and US have forged a landmark trade agreement that will keep no levies on British drug exports going into the US market.
The Terms of the Deal
Under the terms of the agreement, the UK has agreed to raise expenditure on drugs through the National Health Service (NHS). This commitment guarantees that duties on these vital goods will remain at nothing for a timeframe of three years.
This deal follows earlier statements to dramatically increase tariffs on patented pharmaceutical products, with figures discussed reaching 100%.
"This deal with the Britain bolsters the global environment for new treatments and introduces much-needed fairness to transatlantic drug exports," a release noted.
Economic Importance
Pharmaceuticals constitute one of the the United Kingdom's biggest goods shipped to the US, which is clearly the biggest market for large companies like GSK and AstraZeneca.
Statistics indicate that in the year to the end of last September, the UK sold medicines worth over eleven billion pounds to the US. This amount made up nearly one-fifth of British export trade in that span.
"This agreement protects jobs, stimulates funding and paves the way for the UK to become a global hub for biotech and pharma," a minister commented.
Specific NHS Changes
The pact entails several key commitments from the United Kingdom:
- Revised Affordability Limit: The UK will lift the affordability limit at which it considers new treatments to be unaffordable by twenty-five percent.
- Increased NHS Spending: There is a goal to raise total NHS spending on treatments from 0.3 percent of Gross Domestic Product to 0.6 percent over the next decade.
- Refund Ceiling: The amount pharmaceutical firms must refund to the NHS to prevent overspending will be restricted at 15%. Previously, repayments topped 20%.
Recent Tensions
This agreement comes amid a ongoing tension between the sector and the ministers over medicine costs and regulatory access.
The disagreement were heightened by claims that American customers were charged a premium for the same drugs than people in the other developed nations.
Over the last 18 months, several major drug company projects in the UK have been delayed or cancelled, while major expansions have been announced toward American operations.
One official acknowledged that the NHS needed to spend more on medicines, noting that its spending on drugs had shrunk as a share of its overall budget over the past decade.
